Abstract:Purpose of review: Programmed cell death protein-1 (PD-1) is currently the most extensively studied inhibitory checkpoint molecule. Many malignant neoplasms express the PD-1 ligands, PD-L1, and/or PD-L2, which bind to PD-1 on T cells and induce T cell "exhaustion." By doing so, the malignant cells escape from an antitumor immune response (immune evasion). Blockade of the PD-1/PD-L1 pathway releases T cells from the inhibitory effects exerted by tumor cells and restores a T cell-mediated antitumor immune response. Here, we focus on understanding the immune biology of the PD-1/PD-L1 pathway in large-cell lymphomas, including classic Hodgkin lymphoma (CHL), diffuse large B cell lymphoma (DLBCL), and anaplastic large-cell lymphoma (ALCL), and the current status of PD-1 blockade immunotherapy in treating patients with these lymphomas. Recent findings: PD-1/PD-L1 pathway and PD-1 inhibitors have been widely tested in patients with a variety of lymphomas. Nivolumab and pembrolizumab have been approved by the U.S. Food and Drug Administration for treating patients with some types of relapsed or refractory (R/R) lymphomas. The highest response rate has been achieved in patients with CHL, due to a high frequency of genetic alterations of 9p24.1 and high expression of PD-1 ligands. The frequency of alterations of chromosome 9p24.1 and expression of PD-L1/PD-L1 in DLBCL (except some specific subtypes) is low; therefore, it is not recommended to treat unselected DLBCL patients with PD-1 inhibitors. Studies have shown a high frequency of PD-L1 expression in ALCL, especially in anaplastic lymphoma kinase (ALK)+ type. Several cases reports have described a dramatic and durable response to PD-1 blockade in patients with R/R ALCL, suggesting that patients with R/R ALCL may be potential candidates for PD-1 blockade immunotherapy. Understanding the immune biology of lymphoid neoplasms has helped us identify the specific lymphoma types that are vulnerable to PD-1 inhibitors, such as CHL, and specific subtypes of DLBCL. However, our knowledge of many other lymphomas, including ALCL, in this area is still very limited and the future of PD-1 inhibitors in treating those lymphomas remains unclear.

PD-1/PD-L1 Signaling Pathway and Its Anti-Tumor Effect in Lymphoma——Review

[Research Advances on Programmed Cell Death Receptor-1 Antibody in the Treatment of Lymphoma--Review]

PD-1/PD-L1 Pathway and Its Blockade in Patients with Classic Hodgkin Lymphoma and Non-Hodgkin Large-Cell Lymphomas

PD-1/PD-Ls SignaI Pathway and the Appiication of Anti-Pd-1/pd-ls Antibodies in Cancer Therapy

Contribution of PD-L1 to oncogenesis of lymphoma and its RNAi-based targeting therapy.

Expression of PD-L1 in lymphoma and its effect on lymphoma proliferation and chemotherapy resistance]

Advances of PD-1/PD-L1 Inhibitors in Tumor Immunotherapy

PD-1/PD-L1 pathway: current researches in cancer.

PD-1/PD-L1 Pathway: A Therapeutic Target in CD30+ Large Cell Lymphomas

Research progress of therapeutic effects and drug resistance of immunotherapy based on PD-1/PD-L1 blockade

Regulation mechanism of PD-L1 expression and its effect on antitumor immune responses

The emerging roles of PD-L1 subcellular localization in tumor immune evasion

PD-1/PD-L1 Checkpoint Inhibitors in Tumor Immunotherapy

PD-1 and its ligands are important immune checkpoints in cancer

Checkpoint Inhibitors Hodgkin Lymphoma and Non-Hodgkin Lymphoma

Progress of research on PD-1/PD-L1 in leukemia

Programmed Death Ligand 1 (PD-L1) Expression in Lymphomas: State of the Art

[Progress in Research on Tumor Immune PD-1/PD-L1 Signaling Pathway in Malignant Bone Tumors].

Expression and Clinical Value of Programmed Cell Death-Ligand 1 (PD-L1) in Diffuse Large B Cell Lymphoma: a Retrospective Study

Programmed death-1 ligands PD-L1 and PD-L2 show distinctive and restricted patterns of expression in lymphoma subtypes